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Abstract: Aims: This study aims to identify differences in diabetes specific health related quality of life (HRQoL) in 
children and adolescents with type 1 diabetes mellitus (T1D) treated with three distinct types of intensive insulin therapy-
multiple daily injection (MDI), continuous subcutaneous insulin infusion (CSII) and flexible multiple daily injection (fMDI). 
Materials and Methods: This survey was conducted in north west Tasmania over a 6-month period, during quarterly clinic 
visits. A well-known, reliable and validated survey tool -Paediatric Quality of life (PedsQL) Diabetes Module 3.0 was used to 
capture information about the diabetic specific HRQoL in children and adolescents. The parent-proxy version of the forms was 
completed by the parents electronically using iSurvey application to secure information regarding their children’s diabetes 
related symptoms (11 items), treatment barriers (4 items), treatment adherence (7 items), worry (3 items) and communication 
(3 items). All de-identified information was downloaded into an excel spreadsheet and SPSS V24.0 for further analysis. 
Results: 34 parents completed the electronic data forms on iSurvey. There were no statistically significant differences in 
HRQoL among the CSII, MDI and fMDI groups as determined by one-way ANOVA in diabetes {F (2, 31) = 0.517, p = 0.601}, 
treatment {F (2, 31) = 0.385, p = 0.684}, worry {F (2, 31) = 0.076, p = 0.927}, and communication {F (2, 31) = 0.672, p = 
0.518}. Conclusion: Although, the impact of T1D on the HRQoL in children and adolescents is higher than the children 
without T1D, it appears to be independent of the types of three intensive insulin therapy generally used- CSII, MDI and fMDI, 
suggesting type of insulin therapy may not be the major influencing factor for children’ quality of life as revealed in this first 
of its kind study. A further study with higher number of participants and the additional impact of various glucose monitoring 
systems on the HRQoL is highly recommended, which may influence the decision of right therapy suitable for the entire 
family. 
Keywords: Type 1 Diabetes Mellitus, Continuous Subcutaneous Insulin Infusion, Flexible Multiple Daily Injection, 
Multiple Daily Injection, Health Related Quality of Life,  
Paediatric Quality of life (PedsQL) Diabetes Module 3.0 
 
1. Introduction 
Type 1 diabetes mellitus (T1D): type 1 diabetes mellitus, 
CSII: Continuous Subcutaneous Insulin Infusion, HbA1c: 
Glycosylated haemoglobin, MDI: Multiple Daily Injection, 
fMDI: Flexible Multiple Daily Injection, SH: Severe 
Hypoglycaemia, DKA: Diabetic Ketoacidosis, CGM: 
Continuous Glucose Monitoring, HRQoL: Health Related 
Quality of Life, D-HRQoL: Diabetes Specific Health Related 
Quality of Life, AP: Artificial Pancreatic System. 
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Type 1 diabetes mellitus (T1D) is one of the most common 
chronic medical conditions in children and young adults 
equally affecting males and females with a significant impact 
on the health-related quality of life (HRQoL) particularly in 
adolescents. [1] Although, it affects nearly half a million 
people worldwide, fortunately, the overall incidence has not 
risen over the last 15 years in Australia. [2] The impact on 
HRQoL seems to be less in T1D than some of the other 
chronic common paediatric problems such as ADHD, as 
shown in a recent study in Scotland. [3] HRQoL in children 
with T1D is influenced by multiple clinical and 
sociodemographic factors including age, gender, duration of 
diabetes, needle phobia, fear of hypoglycaemia, associated 
comorbidities and complications, mode of insulin 
administration and associated glucose measurement systems 
such as finger pricking, flash glucometer and continuous 
glucose monitoring (CGM) and finally cognitive and 
affective resources of the entire family. The availability of 
technologies such as flash glucometer, CGMs, devices with 
reduced needs for injection prick (e.g. i-port advance), sensor 
augmented insulin pump, artificial pancreatic system and 
different types of insulin analogues usage are all 
continuously changing the way T1D is treated and therefore, 
its impact on the HRQoL. It is also to be remembered that 
emerging technologies can often be counterproductive due to 
digital information overload. 
Intensive insulin therapy is the gold standard for the 
management of T1D, replacing the twice daily (BD) insulin 
dosing following the outcome report of the landmark 
Diabetes Control and Complication Trial, conducted over a 
period of three decades. [4] Three different types of intensive 
therapy are currently practiced worldwide– continuous 
subcutaneous insulin infusion (CSII) delivered by pump and 
multiple daily injection -either by fixed dose (MDI) or by 
flexible dose (fMDI) depending on the meal-time 
carbohydrate intake. Over time, insulin treatment regimens 
have changed worldwide with the primary aim to improve 
glycaemic control. However, treatment satisfaction and 
HRQoL are equally important before selecting the right type 
of insulin therapy suitable for the entire family. There are 
number of studies showing the glycaemic control in two 
types of insulin therapy, comparing the CSII and MDI, the 
largest being the analysis of SWEET (Better control in 
Paediatric and Adolescent diabeteS: Working to crEate 
CEnTers of Reference) registry which included 16,570 
children with T1D showing that both HbA1c and daily 
insulin dose (U/kg/d) remained decreased in children treated 
with CSII compared to MDI (P < .0001) both in pre-schooler 
and school aged children. [5] Another meta-analysis 
consisting of seven RCTs involving a total of 220 children 
with T1D demonstrated that CSII was associated with 
statistically significant, marginal decrease in HbA1c level 
(MD = -0.24%, 95% CI = -0.41 to -0.07) without significant 
differences in episodes of severe hypoglycaemia (SH) and 
diabetic ketoacidosis (DKA) than MDI [6]. 
Fixed dose MDI is administered as a combination of long 
acting basal insulin injection and a fixed amount of meal-
time boluses, ideally given 15 minutes before the meal. 
CSII offers added advantage over fixed dose MDI, 
requiring less number of injections (usually takes 3 days of 
needle change) but most importantly, can give variable 
basal rate depending on the time of the day, which is more 
physiological. This can also offer meal-time flexibility, 
easier management during the sports days and can 
administer a correction dose without pricking any extra 
injection. This is often considered as a life-style choice. 
However, not everyone with T1D wishes to use CSII. An 
alternative way of intensive insulin treatment was 
developed using flexible multiple daily injection (fMDI), 
which is gaining popularity. The concept of fMDI offers 
better meal-time flexibility in dietary selection yet having 
good glycaemic control. For both CSII and fMDI to be 
effective carbohydrate counting is essential. A study in UK 
suggested that the training promoting dietary freedom 
involving carbohydrate counting has been very effective 
and it improved the HRQoL and glycaemic control in 
people with T1D without worsening severe hypoglycaemia 
or cardiovascular risk. [7] In another study in 2002, at the 
Children’s Hospital of Wisconsin Diabetes Center, USA, a 
significant improvement in HbA1c in prepubertal 
(9.3%±1.3% vs. 8.0%±1.1%, p<0.002) and pubertal 
subjects (9.2%±1.0% vs. 8.2%±0.9%, p<0.001) with fMDI 
compared to the conventional therapy was demonstrated. 
Most importantly, the rate of severe hypoglycaemia 
decreased in both prepubertal (p<0.01) and pubertal 
(p<0.05) groups. [8] No study, to our knowledge, has 
previously compared the glycaemic control and HRQoL in 
all three types of intensive insulin therapy namely MDI, 
fMDI and CSII. 
Generally, children with T1D report similar HRQoL as the 
rest of the population of the same age with slightly worse 
physical well-being even among those aged 11-17 years with 
early-onset T1D. [9, 10] However, a study from Greece had 
suggested that HRQoL in T1D is worse than the general 
population. In addition, HRQoL has been noticed to be 
perceived differently, parents of children and adolescents 
with T1D reported that the illness had a greater effect on 
their children's lives than the children perceived themselves. 
Later age of onset of diabetes, less hyperglycaemic episodes, 
lower HbA1c, older age, and male gender were associated 
with better general HRQoL and diabetes-specific HRQoL. [1, 
11] In our study we aimed to understand the impact of 
various types of intensive insulin therapy - CSII, MDI and 
fMDI on HRQoL in children with T1D. To our knowledge 
this is first of its kind comparing all three types. 
2. Materials and Methods 
2.1. Participants 
A total of 35 parents of children with T1D were enrolled 
for the study during their quarterly multidisciplinary diabetic 
clinic visits. Children were utilising one of three types of 
insulin regimen- fMDI, MDI and CSII. 
8 Anutosh Shee et al.:  Parent-Reported Diabetic-Specific Health Related Quality of Life in Children Treated with MultipleDaily  
Injection, Continuous Subcutaneous Insulin Infusion and Flexible Multiple Daily Injection: A Comparative Study 
2.2. Procedure 
This survey-based study was conducted with the approval 
of and in accordance with the policies and procedures of the 
University of Tasmania Health and Medical Human Research 
Ethics Committee. After obtaining informed consent, parents 
were administered a self-report questionnaire containing 
demography questions and Paediatric Quality of Life 
(PedsQL) Diabetes Module 3.0 on an electronic tablet. The 
data was collected electronically via iSurvey and then de-
identified information was downloaded into an ‘Excel 
spreadsheet’ and SPSS V24.0 for further analysis. 
Paediatric Quality of life (PedsQL) Diabetes Module 3.0 
((Information Resources Centre, Mapi Research Trust, 
France) is a reliable and validated tool (both parent proxy-
report and children completed) which assesses diabetes 
specific health-related quality of life in children and 
adolescents. (12) The measure contains separate 
questionnaires relevant to 4 age groups: 2-4 years, 5-7 years, 
8-12 years and 13-18 years. Each questionnaire contains 28 
items within five domains: diabetes symptoms (11 items); 
treatment barriers (4 items); treatment adherence (7 items); 
worry (3 items); and communication (3 items). The 
questionnaire measures items on a 5-point Likert scale where 
the higher score indicates a problem with the domain being 
questioned (0 =never a problem to 4 = almost always a 
problem. Items are then reverse-scored and linearly 
transformed into a Likert scale with a 0– 100 range (0 = 100, 
1 = 75, 2 = 50, 3 = 25, 4 = 0), so that higher scores indicate 
better HRQoL. [12] The summary of the study design is 
explained in the figure 1. 
 
Figure 1. The process of the study. 
3. Results 
3.1. Demographics 
A total of 35 parents of children (M age = 13.4 years, SD = 
3.87 years, Range 3-18 years, 51% female) were enrolled for 
the study. The length of time since diagnosis of T1D ranged 
from 0-15 years (M = 5.52 years, SD = 4.78 years). One 
parent withdrew before administering the questionnaire due 
to time constraint. Twenty parents (59%) were aged between 
30-49 years. Two parents (0.6%) were of aboriginal 
Australian descent. Most of the parents were employed 
(74%), either in a fulltime or casual position. Nearly one-
third (32%) of all respondents were either advanced diploma 
holders or above. Fifty percent of the parents were married. 
Table 1 shows the demographics for the parental group. 
Our study group also indicated only 10% of the children 
with T1D were below 8 years old. Overall, there were equal 
number of males and females affected. More than three-
quarters of all children had acceptable BMI, with 5% being 
obese. Most of the children in our study group were using 
MDI (14/35), followed by CSII (11/35) and fMDI (10/35). 
Fourteen children (40%) had previously switched from MDI 
to a different type of insulin regimen (fMDI or CSII). [Figure 
2] Insulin glargine and insulin aspart/lispro delivered by pen 
were used as a long-acting and meal-time insulin agent, 
respectively for both fMDI and MDI regimen. Only, insulin 
aspart was used for all the children with CSII in our cohort. 
Table 2 shows the demographic information for the patient 
(children) group. 
Table 1. Demographic information of parents of children with type 1 
diabetes. 







Less than year 12 or equivalent 8 
Year 12 or equivalent 4 
Certificate 11 
Advanced Diploma/Diploma 3 
Bachelor’s Degree 3 
Grad Dip/Grad Cert 3 
Master’s Degree 2 
Ethnicity  
Australian 31 
Torres Strait Islander/Aboriginal 1 
Australian Aboriginal 2 
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Variables n = 34 
Employment Status  
Casual employment 7 
Full-time employment 9 
Home duties 8 
Part-time employment 9 
Unemployed 1 




Single-never married 7 
Table 2. Demographic information of children with type 1 diabetes. 
















>9.0 % 15 
8.6% - 9.0% 7 
8.1% - 8.5% 3 
7.6% - 8.0% 5 
6.5% - 7.5% 4 
< 6.5% 1 
Current Treatment  
Insulin Pump (CSII) 11 
Flexible Insulin Dosing (fMDI) 10 
Multiple Daily Injections (MDI) 14 
The item mean scores and standard deviations out of the 
PedsQL Diabetes Module 3.0 questionnaire are presented in 
Table 3 and the relationships between the variables are 
described in Table 4. There were no statistically significant 
differences in diabetic specific HRQoL between the groups 
as determined by a one-way ANOVA- diabetes {F (2, 31) = 
0.517, p = 0.601}, treatment {F (2, 31) = 0.385, p = 0.684}, 
worry {F (2, 31) = 0.076, p = 0.927}, and communication {F 
(2, 31) = 0.672, p = 0.518}. A Tukey post hoc test revealed 
that there were no statistically significant differences 
between the treatment groups (see Table 3). 
 
Figure 2. The pie chart showing the proportion of the children and 
adolescents being treated by CSII, MDI and fMDI. CSII- 31%, MDI- 40% 
and fMDI-29%. 
Table 3. PedsQL summary outcome. 
Statement 
Age Group 







n M (SD) n M n M (SD) n M (SD) n M (SD) 
DIABETES 
(problems with) 
Feeling hungry 2 25 (1.41) 1 75 12 42.5 (0.87) 14 37.5 (0.85) 5 60 (1.14) 
Feeling Thirsty 2 37.5 (0.71) 1 75 12 42.5 (0.75) 14 52.5 (1.0) 5 75 (0.71) 
Having to go to the toilet too often 2 50 (1.41) 1 100 12 65 (0.79) 14 70 (1.15) 5 85 (0.55) 
Having stomach aches 2 87.5 (0.71) 1 100 12 67.5 (0.78) 14 70 (1.03) 5 75 (1.41) 
Having headaches 2 87.5 (0.71) 1 50 12 65 (1.08) 14 67.5 (0.83) 5 80 (0.84) 
Going “low” or “hypo” 2 62.5 (0.71) 1 100 12 45 (1.03) 14 47.5 (0.47) 5 55 (1.10) 
Feeling tired 2 62.5 (0.71) 1 100 12 57.5 (0.65) 14 45 (0.77) 5 70 (0.84) 
Getting shaky 2 87.5 (0.71) 1 100 12 67.5 (0.97) 14 62.5 (0.85) 5 80 (0.84) 
Getting sweaty 2 62.5 (0.71) 1 100 12 72.5 (0.9) 14 70 (0.66) 5 90 (0.89) 
Having trouble sleeping at night 2 50 (1.41) 1 75 12 70 (1.11) 14 62.5 (1.02) 5 90 (0.55) 
Getting grumpy or annoyed 2 50 (1.41) 1 75 12 42.5 (0.97) 14 45 (1.14) 5 75 (1.41) 
TREATMENT 
(Problems with) 
Injections/blood tests causing pain 2 62.5 (0.71) 1 75 12 60 (0.90) 14 60 (1.22) 5 75 (1.00) 
Getting embarrassed about having 
diabetes 
2 87.5  (0.71) 1 100 12 67.5 (1.15) 14 70 (1.35) 5 65 (0.89) 
Arguing with parent about diabetes 
care 
2 75 (0.0) 1 100 12 52.5 (1.31) 14 60 (1.4) 5 80 (1.10) 
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Statement 
Age Group 







n M (SD) n M n M (SD) n M (SD) n M (SD) 
Sticking to diabetes routine 2 50 (1.10) 1 100 12 60 (0.90) 14 45 (1.33) 5 75 (0.71) 
TREATMENT 2  
It is hard for my child to do blood 
glucose tests 
2 75 (0.0) 1 100 12 82.5 (0.98) 14 75 (1.11) 5 90 (0.55) 
It is hard for my child to give 
himself insulin injections 
2 67.5 (2.1) 1 0 12 67.5 (1.42) 14 80 (0.97) 5 80 (0.84) 
It is hard for my child to exercise 2 87.5 (0.71) 1 100 12 85 (0.51) 14 62.5 (1.29) 5 80 (1.10) 
It is hard for my child to follow a 
healthy diet 
2 75 (0.0) 1 100 12 65 (1.08) 14 67.5 (1.27) 5 80 (0.84) 
It is hard for my child to wear his 
id bracelet/necklace or carry a card 
2 87.5 (0.71) 1 0 12 67.5 (1.56) 14 65 (1.55) 5 40 (1.67) 
It is hard for my child to carry a 
fast-acting carbohydrate 
2 75 (0.0) 1 100 12 82.5 (0.78) 14 62.5 (1.02) 5 75 (1.41) 
It is hard for my child to eat snacks 
between meals when they should 
2 87.5 (0.71) 1 100 12 82.5 (0.67) 14 67.5 (1.34) 5 70  (1.10) 
WORRY (problems 
with) 
Worrying about “going low” or 
“hypo” 
2 62.5 (0.71) 1 100 12 50 (1.21) 14 50 (1.11) 5 65 (1.52) 
Worrying about whether or not 
medical treatments are working 
2 62.5 (0.71) 1 100 12 55 (1.11) 14 62.5 (1.16) 5 80 (0.84) 
Worrying about long-term 
problems of diabetes 
2 37.5 (2.12) 1 100 12 45 (1.64) 14 52.5 (1.33) 5 60 (0.89) 
COMMUNICATIO
N (problems with) 
Telling the doctors and nurses how 
he/she feels 
2 37.5 (0.71) 1 100 12 77.5 (1.38) 14 70 (1.20) 5 80 (0.84) 
Asking the doctor or nurses 
questions 
2 75 (1.41) 1 100 12 80 (1.40) 14 72.5 (1.10) 5 90 (0.55) 
Explaining his/her illness to other 
people 
2 75 (1.41) 1 100 12 77.5 (1.24) 14 67.5 (1.07) 5 70 (1.10) 
 
Table 4. Post-hoc comparisons for quality of life. 
Dependent Variable Treatment Mean Difference Sig. 
Diabetes IP MDI 0.154 0.998 
  FID -0.290 0.677 
 MDI IP -0.154 0.998 
  FID -0.264 0.623 
 FID IP -0.250 0.677 
  MDI 0.264 0.623 
Treatment IP MDI 0.018 1.00 
  FID -0.264 0.734 
 MDI IP -0.018 1.00 
  FID -0.265 0.713 
 FID IP 0.264 0.734 
  MDI 0.265 0.713 
Worry IP MDI -0.062 0.977 
  FID 0.058 0.982 
 MDI IP 0.062 0.977 
  FID 0.120 0.921 
 FID IP -0.058 0.982 
  MDI -0.120 0.921 
Communication IP MDI 0.110 0.956 
  FID -0.339 0.692 
 MDI IP -0.110 0.956 
  FID -0.450 0.502 
 FID IP 0.339 0.695 
  MDI 0.449 0.502 
4. Discussion 
Our study was conducted in a regional centre in Tasmania, 
which has the highest prevalence of T1D in children among all 
the Australian states, being 166 per 100,000 population and its 
demographic features were similar to the overall national trends 
as per the Australian Institute of Health and Welfare, 2013 
report. (2) Like the national figure, T1D rates were similar for 
both males and females. Rates for children aged 10–14 were 
more than 10 times higher than for children aged 0–4. Treatment 
regimen data also showed that nearly one-third of children in our 
study used CSII as opposed to 43% nationwide. 
Diagnosis of diabetes is a life changing experience for the 
whole family unit. The management of diabetes is 
complicated, as treatment affects the everyday life of both 
children and their families. For the optimal care of children 
with T1D, it is important to highlight the importance of 
HRQoL as well as glycaemic control. HRQoL is an 
important factor which strongly influences the glycaemic 
control and psychosocial functioning. [13] In this study we 
identified no significant difference of HRQoL among the 
types of intensive insulin therapy. However, other 
influencing factors of HRQoL are worth reviewing in this 
regard. Types of diabetic complication, for example, exert 
variable impact on HRQoL, like the presence of nephropathy, 
but not retinopathy, reduced the subjective HRQoL in 
patients with T1D. [14] Tighter glycaemic control is 
unequivocally associated with better HRQoL. [15] While 
managing the children with T1D, various protective factors 
are important to recognise and should be promoted whenever 
possible for better HRQoL. Greater child protective factors 
are associated with better diabetes resilience, including 
higher child HRQoL and lower parental depression and stress. 
Generally, a positive correlation is found between the child's 
age whereas a negative correlation is found between the 
number of children in the family and the HRQoL of the child 
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and parents. [16]. Child’s gender also plays an important role. 
To identify the main factors influencing the diabetic specific 
HRQoL (D-HRQoL), the TEENs study which was an 
international, cross-sectional study of youth between 8 to 25 
years of age, with T1D, found across all age groups, females 
reported significantly lower D-HRQoL than did males. Better 
glycaemic control, advanced methods used to measure food 
intake, more frequent daily blood glucose monitoring and 
more days of physical activity were all associated with better 
HRQoL. [17] Other studies have also found that girls seem to 
need extra support. [18]. 
There are number of comparative studies available to look at 
the HRQoL in children treated with either MDI or CSII. In 
Denmark, for example, parents reported children and 
adolescents on CSII for more than one year have less diabetes-
related symptoms and worry, less problems in communicating 
diabetes, and better generic functioning compared with those on 
MDI. For less than one year, there was, however, no differences 
identified, apart from the less treatment barriers in the MDI. [19] 
Adding CGM to CSII significantly improves metabolic control 
but interestingly had no positive impact on HRQoL in children. 
[20] Physical activity has been curiously investigated as a 
potential influencing factor for D-HRQoL. Higher Vo2max and 
the CSII therapy were significant predictors of the better 
HRQoL, however, other clinical and anthropometric variables 
did not have any effect in a study conducted to identify the 
factors influencing the D-HRQoL. The good cardiorespiratory 
fitness (expressed by Vo2max) has been found to have clinical 
and HRQoL benefits for paediatric patients with T1D. [21]. 
Comorbidities are also an important factor in the 
management of T1D. Previous studies results show that 
living with an additional disease, such as psychiatric illnesses, 
has an impact on the HRQoL. [22] There were nearly 26.6% 
children and adolescents with T1D with comorbid psychiatric 
illness as identified in previous studies. The most common 
diagnoses were: anxiety (N=32; 15.5%) and mood disorders 
(N=8; 3.9%). One-third of the patients (31.9%) met the 
criteria for at least one psychiatric diagnosis in a lifetime 
period. The presence of psychiatric disorders was related 
with elevated HbA1c (8.6% vs. 7.6%) and lowered HRQoL 
in the general PedsQL. In the diabetes-specific PedsQL 
children with psychiatric disorders revealed more symptoms 
of diabetes, treatment barriers and lower adherence than 
children without psychiatric disorders. [23] Comorbidities 
also play an important role in parental satisfaction. HRQoL 
and glycaemic control in youth with T1D and coeliac disease 
vs T1D only were compared. Youth with T1D and celiac 
disease who do not adhere to the gluten-free diet have lower 
HRQoL and worse glycaemic control. [24]. 
Insulin type and timing in relation to meal time is also 
important factor for HRQoL. Although pre-prandial 
administration of insulin aspart is generally preferable, one 
study found that in children and adolescents, postprandial 
administration of insulin aspart is a safe and effective 
alternative.(25) When diabetes is diagnosed, multiple 
injections become a part of daily life. It is estimated that 22% 
of general population has needle phobia, often shared by 
several family members. Also, in phobic children multiple 
injections therapy can induce discomfort and pain. Effectivity 
of indwelling catheter on metabolic control and HRQoL in 
children and adolescents with T1D and in their mothers 
suggested HbA1c significantly improved 3 months after the 
application of the device (p=0.002). This improvement was 
preserved up to 1 year, with improvement of clinically 
significant stress from 53% to 3% of children and 
adolescents, suggesting the use of i-Port Advance improves 
the quality of life of caregivers and children, as well as the 
metabolic control. [26] Another useful component aiming to 
improve the treatment outcome, telephone calls from a 
paediatric diabetes educator to children who have T1D were 
regularly attempted to identify its impact on HbA1c level, 
hospital admissions, diabetes knowledge, compliance, and 
psychological well-being. This had shown there was no 
significant difference between the treatment and control 
groups either before or after the intervention. Scheduled 
bimonthly phone support does not improve the HbA1c level, 
admission rates, diabetes knowledge, psychological function, 
or self-management but is perceived by patients as helpful. 
[27] For young children with T1D, CSII therapy is 
comparable to MDI therapy with regard to glucose control 
but is associated with higher treatment satisfaction and 
improved HRQoL. [28] Our study added that the type of 
intensive therapy did not make any statistically significant 
difference on the HRQoL. 
5. Limitations 
1. Small sample size  
2. Modes of associated glucose estimation were not looked 
at in this study. Different children on various glucose 
monitoring systems like finger-prick glucometer, flash 
glucometer or CGM may have the variable influencing effect 
on HRQoL. 
6. Conclusion 
Although, the impact of T1D on the HRQoL in children 
and adolescents is higher than the children without T1D, it 
appears to be independent of the types of three intensive 
insulin therapy generally used- CSII, MDI and fMDI, 
suggesting type of insulin therapy may not be the major 
influencing factor for children’ quality of life as revealed in 
this first of its kind study. A further study with higher 
number of participants and the additional impact of various 
glucose monitoring systems on the HRQoL is highly 
recommended, which may influence the decision of right 
therapy suitable for the entire family 
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